Hiroaki Suga

This paper introduces RiPLE, a method for discovering engineered protein binders, and shows it produces high-affinity, selective binders for ROR1 and GS.

The paper develops macrocyclic peptides that target HAP40, enabling the study of HTT-HAP40 interactions and their role in Huntington's disease.

The paper develops a macrocyclic peptide WJL-63 with high ACE2-binding affinity and characterizes its structure and potential for imaging applications.

This study develops a framework to design peptides that modulate α-synuclein phase separation by integrating deep mutational scanning and peptide screening.

This study investigates the substrate specificity of the PEARL BhaBCAla, showing it can use non-cognate amino acids and tRNAs for peptide extension, with efficiency depending on both amino acid and tRNA features.

The paper identifies cyclic peptides that selectively inhibit BET BD paralogues by exploiting sequence differences and conformational dynamics, achieving high selectivity over existing inhibitors.

This paper identifies and characterizes high-affinity, selective macrocyclic peptide ligands for Huntingtin, enabling structural and functional studies of HTT and its complex with HAP40.

The paper develops cyclic peptide modulators of PADI4 and reveals their mechanism of action and cellular activity.

This study identifies chemically constrained peptides that inhibit PfUCHL3, a critical deubiquitinating enzyme in Plasmodium falciparum, by blocking substrate binding rather than active site interaction.